Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging.
Chéreau
Elisabeth
E
Department of Surgery, Breast Cancer Group, Institut Gustave Roussy, Villejuif, France. elisabeth.chereau@gmail.com
Uzan
Catherine
C
Balleyguier
Corinne
C
Chevalier
Julie
J
de Paillerets
Brigitte Bressac
BB
Caron
Olivier
O
Rimareix
Françoise
F
Mathieu
Marie-Christine
MC
Koskas
Martin
M
Bourgier
Céline
C
André
Fabrice
F
Dromain
Clarisse
C
Delaloge
Suzette
S
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006801:Humans; D053208:Kaplan-Meier Estimate; D008279:Magnetic Resonance Imaging; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D011878:Radiotherapy; D021701:Sentinel Lymph Node Biopsy; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents